Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients

Infertility Clinical Trial

Official title:

Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Clinical Pregnancy Outcome in Repeated Implantation Failure Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02870855
• Other study ID #: KYXM-201604
• Status: Withdrawn
• Phase: N/A
• Start date: July 28, 2017
• Est. completion date: January 1, 2018

Study information

• Verified date: January 2022
• Source: Reproductive & Genetic Hospital of CITIC-Xiangya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Repeated implantation failure（RIF） is a insurmountable bottleneck in assisted reproductive technology, many studies have considered that the cause of two-thirds of implant failure is the decreased endometrial receptivity. Human chorionic gonadotropin (hCG) is an early pre-plant signal molecule secreted by the embryo, it can promote endometrial proliferation, increase blood flow and promote embryonic adhesion and inhibit self-regulate apoptosis of trophoblast cells. Previous studies showed that: intrauterine injection of HCG before embryo transfer can improve clinical outcomes in IVF/Intracytoplasmic sperm injection(ICSI). But some studies found that the intrauterine injection of HCG can not significantly improve the success rate of blastocyst transfer, and the reason may be the intrauterine injection of HCG time is too late to significantly increase the implantation rate. Would ahead of intrauterine injection of HCG be more effective? Thus, the patients of repeated implantation frozen embryo cycle according to the random principle accepted two kinds of transplants ways: ①intrauterine injection of HCG before blastocyst transfer; ②blastocyst transfer. Try to understand whether intrauterine injection of HCG can significantly improve the clinical pregnancy rate of blastocyst transfer in repeated implantation failure patients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2018
• Est. primary completion date: January 1, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• women with unexplained RIF(two to four previous embryo transfers without achieving pregnancy);

• age<36 years;

• frozen embryo transfer cycles

Exclusion Criteria:

• polycystic ovary syndrome

• uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and uterine mediastinum)

• intrauterine adhesions

• endometriosis

• adenomyosis

• hydrosalpinx

• uterine fibroids (submucosal fibroids, non-mucosal fibroids > 4 cm and / or endometrial pressure)

• thydroid dysfunction and hyperprolactinemia

Related Conditions & MeSH terms

• Infertility

Intervention

Drug:
• intrauterine injection of HCG
intrauterine injection of HCG berore blastocyst transfer

Locations

Country	Name	City	State
China	Reproductive & Genetic Hospital of CITIC-XIANGYA	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Reproductive & Genetic Hospital of CITIC-Xiangya

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	clinical pregnancy rate	clinical pregnancy rate	Until 28 day after embryo transferred
Secondary	spontaneous abortion rate	spontaneous abortion rate	until 28 day after embryo transferred
Secondary	ectopic pregnancy rate	ectopic pregnancy rate	until 28 day after embryo transferred